Abstract
Glycogen storage disease type Ia (GSD-Ia) is caused by a deficiency in glucose-6-phosphatase-α (G6Pase-α), a nine-transmembrane domain, endoplasmic reticulum-associated protein expressed primarily in the liver and kidney. Previously, we showed that infusion of an adeno-associated virus (AAV) serotype 2 vector carrying murine G6Pase-α (AAV2-G6Pase-α) into neonatal GSD-Ia mice failed to sustain their life beyond weaning. We now show that neonatal infusion of GSD-Ia mice with an AAV serotype 1-G6Pase-α (AAV1-G6Pase-α) or AAV serotype 8-G6Pase-α (AAV8-G6Pase-α) results in hepatic expression of the G6Pase-α transgene and markedly improves the survival of the mice. However, only AAV1-G6Pase-α can achieve significant renal transgene expression. A more effective strategy, in which a neonatal AAV1-G6Pase-α infusion is followed by a second infusion at age one week, provides sustained expression of a complete, functional, G6Pase-α system in both the liver and kidney and corrects the metabolic abnormalities in GSD-Ia mice for the 57 week length of the study. This effective use of gene therapy to correct metabolic imbalances and disease progression in GSD-Ia mice holds promise for the future of gene therapy in humans.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chou JY, Matern D, Mansfield BC, Chen YT . Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med 2002; 2: 121–143.
Chen Y-T . Glycogen storage diseases. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds). The Metabolic and Molecular Bases of Inherited Disease, 8th edn. McGraw-Hill Inc.: New York, 2001, pp 1521–1551.
Greene HL, Slonim AE, O'Neill Jr JA, Burr IM . Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease. N Engl J Med 1976; 294: 423–425.
Chen YT, Cornblath M, Sidbury JB . Cornstarch therapy in type I glycogen storage disease. N Engl J Med 1984; 310: 171–175.
Lei K-J et al. Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a. Science 1993; 262: 580–583.
Shelly LL et al. Isolation of the gene for murine glucose-6-phosphatase, the enzyme deficient in glycogen storage disease type 1a. J Biol Chem 1993; 268: 21482–21485.
Pan C-J et al. Ontogeny of the murine glucose-6-phosphatase system. Arch Biochem Biophys 1998; 358: 17–24.
Nordlie RC, Sukalski KA . Multifunctional glucose-6-phosphatase: a critical review. In: Martonosi AN (ed). The Enzymes of Biological Membrane, 2nd edn. Plenum Press: New York, 1985, pp 349–398.
Pan C-J et al. Transmembrane topology of glucose-6-phosphatase. J Biol Chem 1998; 273: 6144–6148.
Ghosh A et al. The catalytic center of glucose-6-phosphatase: His176 is the nucleophile forming the phosphohistidine-enzyme intermediate during catalysis. J Biol Chem 2002; 277: 32837–32842.
Chou JY, Mansfield BC . Glucose-6-phosphate transporter: the key to glycogen storage disease type Ib. In: Broer S, Wagner CA (eds). Membrane Transporter Diseases. Kluwer Academic/Plenum Publisher: New York, 2003, pp 191–205.
Hiraiwa H et al. Inactivation of the glucose-6-phosphate transporter causes glycogen storage disease type 1b. J Biol Chem 1999; 274: 5532–5536.
Lei K-J et al. Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type 1a mouse. Nat Genet 1996; 13: 203–209.
Zingone A et al. Correction of glycogen storage disease type 1a in a mouse model by gene therapy. J Biol Chem 2000; 275: 828–832.
Sun M-S et al. Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice. Hum Mol Genet 2002; 11: 2155–2164.
Thomas CE, Storm TA, Huang Z, Kay MA . Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 2004; 78: 3110–3122.
McCarty DM, Young Jr SM, Samulski RJ . Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004; 38: 819–845.
Flotte TR . Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 2004; 11: 805–810.
Tenenbaum L, Lehtonen E, Monahan PE . Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 2003; 3: 545–565.
Benihoud K, Yeh P, Perricaudet M . Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999; 10: 440–447.
Wilson JM . Adenovirus-mediated gene transfer to liver. Adv Drug Deliv Rev 2001; 46: 205–209.
Chao H et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2: 619–623.
Gao GP et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854–11859.
Grimm D, Kay MA . From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003; 3: 281–304.
Rabinowitz JE et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791–801.
Loiler SA et al. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Therapy 2003; 10: 1551–1558.
Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF . Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001; 38: 1782–1787.
Hauck B, Chen L, Xiao W . Generation and characterization of chimeric recombinant AAV vectors. Mol Ther 2003; 7: 419–425.
Ponnazhagan S et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 1997; 190: 203–210.
Daly TM . AAV-mediated gene transfer to the liver. Methods Mol Biol 2004; 246: 195–199.
Shieh J-J, Pan C-J, Mansfield BC, Chou JY . Glucose-6-phosphate hydrolase, widely expressed outside the liver, can explain age-dependent resolution of hypoglycemia in glycogen storage disease type Ia. J Biol Chem 2003; 278: 47098–47103.
Guionie O, Clottes E, Stafford K, Burchell A . Identification and characterisation of a new human glucose-6-phosphatase isoform. FEBS Lett 2003; 551: 159–164.
Clore JN, Stillman J, Sugerman H . Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes. Diabetes 2000; 49: 969–974.
Liu Z et al. Effect of acute diabetes on rat hepatic glucose-6-phosphatase activity and its messenger RNA level. Biochem Biophys Res Commun 1994; 205: 680–686.
Haber BA et al. High levels of glucose-6-phosphatase gene and protein expression reflect an adaptive response in proliferating liver and diabetes. J Clin Invest 1995; 95: 832–841.
Xu L et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001; 12: 563–573.
Grimm D, Kern A, Rittner K, Kleinschmidt JA . Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998; 10: 2745–2760.
Zolotukhin S et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002; 28: 158–167.
Nathwani AC et al. Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38− subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV. Gene Therapy 2000; 7: 183–195.
Hauswirth WW, Lewin AS, Zolotukhin S, Muzyczka N . Production and purification of recombinant adeno-associated virus. Methods Enzymol 2000; 316: 743–761.
Teutsch HF . Chemomorphology of liver parenchyma. Qualitative histochemical distribution patterns and quantitative sinusoidal profiles of G6Pase, G6PDH and malic enzyme activity and of glycogen content. Prog Histochem Cytochem 1981; 14: 1–92.
Acknowledgements
We gratefully acknowledge the University of Florida Powell Gene Therapy Center Vector Core laboratory, which produced the recombinant AAV vectors used in this study. This work was partially supported by the program project grant to BJB (#DK58327) from the National Institute of Diabetes and Digestive and Kidney Diseases.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghosh, A., Allamarvdasht, M., Pan, CJ. et al. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Gene Ther 13, 321–329 (2006). https://doi.org/10.1038/sj.gt.3302650
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302650
Keywords
This article is cited by
-
Long‐term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia
Journal of Inherited Metabolic Disease (2018)
-
In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA
Molecular Therapy (2016)
-
Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease
Journal of Inherited Metabolic Disease (2015)
-
Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy
Kidney International (2014)